NCT05356637 is a NA clinical trial of Werewolf Fastseal 6.0 in Osteoarthritis, Hip, sponsored by North Texas Medical Research Institute, PLLC.

Who is sponsoring NCT05356637?

NCT05356637 is sponsored by North Texas Medical Research Institute, PLLC.

What drugs are being tested in NCT05356637?

Interventions in NCT05356637: Werewolf Fastseal 6.0.

What condition does NCT05356637 study?

NCT05356637 studies Osteoarthritis, Hip, Blood Loss.

Is NCT05356637 still recruiting?

NCT05356637 is currently status unknown. Last updated 31 October 2023.

Last reviewed 2023-10-31 · How we verify

NCT05356637

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bipolar Sealer for Reduction of Blood Loss in Anterior Total Hip Arthroplasties

Status unknown NA Last updated 31 October 2023

What this trial tests

NA trial testing Werewolf Fastseal 6.0 in Osteoarthritis, Hip in 75 participants. Status unknown.

Timeline

29 April 2022

Primary endpoint
31 January 2024

1 February 2024

Quick facts

Lead sponsor	North Texas Medical Research Institute, PLLC
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	75
Start date	29 April 2022
Primary completion	31 January 2024
Estimated completion	1 February 2024
Sites	2 locations across United States

Drugs / interventions tested

Werewolf Fastseal 6.0

Conditions studied

Osteoarthritis, Hip — all drugs for Osteoarthritis, Hip →
Blood Loss — all drugs for Blood Loss →

Sponsor

North Texas Medical Research Institute, PLLC

Who can join

21 and older, any sex, with Osteoarthritis, Hip or Blood Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall objectives and purpose of this study is to show that the Smith and Nephew Werewolf Fastseal 6.0 Bipolar Sealer is an effective tool to aide the surgical team in providing significant hemostasis during anterior total hip arthroplasty which would subsequently improve patient outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Osteoarthritis, Hip

Currently open trials in the same condition.

NCT07386561 — Virtual Reality Therapy and Non-Sleep Deep Rest Relaxation After Joint Arthroplasty · NA · active not recruiting
NCT06578182 — The Effect of ColcHicine on the Incidence of Knee or Hip Replacements · Phase 3 · recruiting
NCT06342843 — Direct Superior Approach Versus PosteroLateral Approach in Total Hip Arthroplasty (SPLAsH) · NA · recruiting
NCT06249958 — Transforming Rehabilitation: Personalised Care for a Better Quality of Life · recruiting
NCT05700682 — Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05356637 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by North Texas Medical Research Institute, PLLC
Last refreshed: 31 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05356637.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing